loading...| Preferred Name |
Fenofibrate |
|
| Synonyms |
FENOFIBRATE fenofibrate Fenofibrate Lofibra TriCor Tricor |
|
| Definitions |
A synthetic phenoxy-isobutyric acid derivate and prodrug with antihyperlipidemic activity. Fenofibrate is hydrolyzed in vivo to its active metabolite fenofibric acid that binds to and activates peroxisome proliferator activated receptor alpha (PPARalpha), resulting in the activation of lipoprotein lipase and reduction of the production of apoprotein C-III, an inhibitor of lipoprotein lipase activity. Increased lipolysis and a fall in plasma triglycerides, in turn, leads to the modification of the small, dense low density lipoporotein (LDL) particles into larger particles that are catabolized more rapidly due to a greater affinity for cholesterol receptors. In addition, activation of PPARalpha also increases the synthesis of apoproteins A-I, A-II, and high density lipoprotein (HDL)-cholesterol. Overall, fenofibrate reduces total cholesterol, LDL cholesterol, apolipoprotein B, total triglycerides and triglyceride rich lipoprotein (VLDL) while increasing HDL cholesterol. |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C29047 |
|
| ALT_DEFINITION |
A drug used to treat high levels of cholesterol and triglycerides in the blood. Fenofibrate is being studied in the treatment of advanced cancers in young patients and in the treatment of other conditions. It is a type of antilipidemic agent. |
|
| CAS_Registry |
49562-28-9 |
|
| CHEBI_ID |
CHEBI:5001 |
|
| Chemical_Formula |
C20H21ClO4 |
|
| code |
C29047 |
|
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C173381 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C173383 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 |
|
| Contributing_Source |
CTRP FDA |
|
| DEFINITION |
A synthetic phenoxy-isobutyric acid derivate and prodrug with antihyperlipidemic activity. Fenofibrate is hydrolyzed in vivo to its active metabolite fenofibric acid that binds to and activates peroxisome proliferator activated receptor alpha (PPARalpha), resulting in the activation of lipoprotein lipase and reduction of the production of apoprotein C-III, an inhibitor of lipoprotein lipase activity. Increased lipolysis and a fall in plasma triglycerides, in turn, leads to the modification of the small, dense low density lipoporotein (LDL) particles into larger particles that are catabolized more rapidly due to a greater affinity for cholesterol receptors. In addition, activation of PPARalpha also increases the synthesis of apoproteins A-I, A-II, and high density lipoprotein (HDL)-cholesterol. Overall, fenofibrate reduces total cholesterol, LDL cholesterol, apolipoprotein B, total triglycerides and triglyceride rich lipoprotein (VLDL) while increasing HDL cholesterol. |
|
| Display_Name |
Fenofibrate |
|
| FDA_UNII_Code |
U202363UOS |
|
| FULL_SYN |
FENOFIBRATE fenofibrate Fenofibrate Lofibra TriCor Tricor |
|
| label |
Fenofibrate |
|
| Legacy Concept Name |
Fenofibrate |
|
| NCI_Drug_Dictionary_ID |
459750 |
|
| PDQ_Closed_Trial_Search_ID |
459750 |
|
| PDQ_Open_Trial_Search_ID |
459750 |
|
| Preferred_Name |
Fenofibrate |
|
| prefixIRI |
Thesaurus:C29047 |
|
| Semantic_Type |
Pharmacologic Substance |
|
| UMLS_CUI |
C0033228 |
|
| subClassOf |